Literature DB >> 28242787

TET2 in Normal and Malignant Hematopoiesis.

Robert L Bowman1, Ross L Levine1,2.   

Abstract

The ten-eleven translocation (TET) family of enzymes were originally cloned from the translocation breakpoint of t(10;11) in infant acute myeloid leukemia (AML) with subsequent genomic analyses revealing somatic mutations and suppressed expression of TET family members across a range of malignancies, particularly enriched in hematological neoplasms. The TET family of enzymes is responsible for the hydroxylation of 5-methylcytosines (5-mC) to 5-hydroxymethylcytosine (5-hmC), followed by active and passive mechanisms leading to DNA demethylation. Given the complexity and importance of DNA methylation events in cellular proliferation and differentiation, it comes as no surprise that the TET family of enzymes is intricately regulated by both small molecules and regulatory cooperating proteins. Here, we review the structure and function of TET2, its interactions with cooperating mutations and small molecules, and its role in aberrant hematopoiesis.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28242787      PMCID: PMC5538403          DOI: 10.1101/cshperspect.a026518

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  72 in total

1.  Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein.

Authors:  S Hino; S Kishida; T Michiue; A Fukui; I Sakamoto; S Takada; M Asashima; A Kikuchi
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

Review 2.  FLT3: ITDoes matter in leukemia.

Authors:  M Levis; D Small
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

3.  Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes.

Authors:  Chan H Park; Bruce F Kimler; Seong Yoon Yi; Se Hoon Park; Kihyun Kim; Chul Won Jung; Sun Hee Kim; Eun Ryung Lee; Miyong Rha; Seonwoo Kim; Mary H Park; Sook J Lee; Hye K Park; Mark H Lee; Sung Soo Yoon; Yoo Hong Min; Bong Seog Kim; Jeong-A Kim; Won Seog Kim
Journal:  Eur J Haematol       Date:  2009-03-05       Impact factor: 2.997

4.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

5.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

6.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

7.  Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.

Authors:  Mamta Tahiliani; Kian Peng Koh; Yinghua Shen; William A Pastor; Hozefa Bandukwala; Yevgeny Brudno; Suneet Agarwal; Lakshminarayan M Iyer; David R Liu; L Aravind; Anjana Rao
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

8.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Authors:  Anna M Jankowska; Hadrian Szpurka; Ramon V Tiu; Hideki Makishima; Manuel Afable; Jungwon Huh; Christine L O'Keefe; Rebecca Ganetzky; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

9.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

10.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

View more
  31 in total

1.  Ineffective erythropoiesis of TET2 deficiency.

Authors:  Don M Wojchowski
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

Review 2.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

3.  HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia.

Authors:  John Z Cao; Hui Liu; Amittha Wickrema; Lucy A Godley
Journal:  Blood Adv       Date:  2020-07-14

4.  Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.

Authors:  Yan-Ping Xu; Lei Lv; Ying Liu; Matthew D Smith; Wen-Cai Li; Xian-Ming Tan; Meng Cheng; Zhijun Li; Michael Bovino; Jeffrey Aubé; Yue Xiong
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

Review 5.  Clonal hematopoiesis: Mutation-specific adaptation to environmental change.

Authors:  Marcus A Florez; Brandon T Tran; Trisha K Wathan; James DeGregori; Eric M Pietras; Katherine Y King
Journal:  Cell Stem Cell       Date:  2022-06-02       Impact factor: 25.269

6.  Ten-eleven translocation 2 demethylates the MMP9 promoter, and its down-regulation in preeclampsia impairs trophoblast migration and invasion.

Authors:  Xiaoliang Li; Chunlian Wu; Ying Shen; Ke Wang; Li Tang; Mi Zhou; Ming Yang; Tianying Pan; Xinghui Liu; Wenming Xu
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

Review 7.  The interplay between DNA and histone methylation: molecular mechanisms and disease implications.

Authors:  Yinglu Li; Xiao Chen; Chao Lu
Journal:  EMBO Rep       Date:  2021-04-12       Impact factor: 8.807

8.  Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Authors:  Hassan Awada; Yasunobu Nagata; Abhinav Goyal; Mohammad F Asad; Bhumika Patel; Cassandra M Hirsch; Teodora Kuzmanovic; Yihong Guan; Bartlomiej P Przychodzen; Mai Aly; Vera Adema; Wenyi Shen; Louis Williams; Aziz Nazha; Mohamed E Abazeed; Mikkael A Sekeres; Tomas Radivoyevitch; Torsten Haferlach; Babal K Jha; Valeria Visconte; Jaroslaw P Maciejewski
Journal:  Blood Adv       Date:  2019-02-12

9.  Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine".

Authors:  Feng-Lin Shen; Yan-Na Zhao; Xiao-Ling Yu; Bo-Lin Wang; Xiao-Long Wu; Gao-Chen Lan; Rui-Lan Gao
Journal:  Chin J Integr Med       Date:  2021-07-09       Impact factor: 1.978

10.  Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient.

Authors:  Qiang Ma; Yixian Guo; Xiaoxi Lan; Guoxiang Wang; Wanling Sun
Journal:  BMC Med Genomics       Date:  2021-06-13       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.